Axsome Therapeutics, Inc. (AXSM) is a Biotechnology company in the Healthcare sector, currently trading at $184.18. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is AXSM = $222 (+20.8% upside).
Valuation: AXSM trades at a trailing Price-to-Earnings (P/E) of -47.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.05.
Financials: revenue is $638M, +183%/yr average growth. Net income is $183M (loss), growing at -1.6%/yr. Net profit margin is -28.7% (negative). Gross margin is 92.6% (+3 pp trend).
Balance sheet: total debt is $241M against $88M equity (Debt-to-Equity (D/E) ratio 2.73, leveraged). Current ratio is 1.55 (strong liquidity). Debt-to-assets is 35%. Total assets: $690M.
Analyst outlook: 24 / 25 analysts rate AXSM as buy (96%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 70/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).
